Drug Database
AL

albumin (Pedialb / AlbuRel / AlbuRel LS)

✓ Approved

Reliance Life Sciences Private Limited · Cell-based Therapies · Cell-based Therapies

What is albumin?

albumin is a cell-based therapies developed by Reliance Life Sciences Private Limited. It is approved for therapeutic indications via injectable (others) or intravenous (iv).

Drug Profile

Brand NamesPedialb, AlbuRel, AlbuRel LS
CompanyReliance Life Sciences Private Limited
Drug ClassCell-based Therapies
RouteInjectable (Others), Intravenous (IV)
StatusApproved
Sources: ClinicalTrials.gov, Reliance Life Sciences Private Limited

Therapeutic Indications

albumin is developed for 1 unique indication across 1 therapeutic area.

Therapeutic AreaConditionPhase
Vascular disordersThrombosis✓ Approved

Related Research Articles

PubMedFrontiers in endocrinology2026-11-11

UACR adjustment attenuates associations of selected routine blood markers with documented diabetic retinopathy more than eGFR adjustment: a cross-sectional study in type 2 diabetes.

Zhang Jing J, Xu Mingliang M, Xiong Baoyi B, Luo Baohua B et al.

Studies of routine blood markers and diabetic retinopathy often adjust for estimated glomerular filtration rate (eGFR), although albuminuria captures a different aspect of kidney damage. We compared these associations under eGFR and urinary albumin-to-creatinine ratio (UACR) adjustment. We analyzed 8,159 adults hospitalized with type 2 diabetes from January 2020 to March 2026. Primary exposures were serum albumin, total bilirubin, fibrinogen and the FIB-4 index. Four models were fitted in a fixed complete-case sample, with additional adjustment for eGFR, log UACR, or both. The outcome was documented diabetic retinopathy (DR), based on ophthalmological assessment and discharge diagnosis; DR = 0 included unassessed patients without a DR diagnosis. Prevalence ratios were estimated by marginal standardization. Among 3,978 complete-case patients, 958 (24.1%) had documented DR. Adjustment for log UACR attenuated the serum albumin association more than adjustment for eGFR (73.3% versus 34.3%; difference 38.9 percentage points, 95% CI 30.7 to 49.0) and moved the fibrinogen estimate close to one. Binary albuminuria produced substantially less attenuation than continuous log UACR. Multiple imputation supported the renal-adjustment comparison, although the albumin interval included the null after mutual renal adjustment. Serum albumin remained associated with documented DR after restriction to eGFR ≥90 mL/min/1.73 m2 (prevalence ratio 0.762, 95% CI 0.649 to 0.873), whereas no clear evidence of an eGFR association was observed within this stratum (0.981, P = 0.823). Conclusions: In this single-center inpatient cohort, eGFR and UACR adjustment yielded different estimates for the studied blood-marker associations with documented DR. Attenuation denotes proportional reduction in the absolute log prevalence-ratio estimate, not a causal proportion explained. Dichotomizing UACR discarded information and reduced attenuation in these models.

PMID 43011024
Read full article →
PubMedMedicine2026-11-11

The C-reactive protein-albumin-lymphocyte (CALLY) index in early hospital presentation and intravenous thrombolysis in acute ischemic stroke: A retrospective study.

Basa Kalafat Ayşe Fethiye AF, Güner Muhammed M, Olcay Elif Gizem EG, Karadeniz Feyza F et al.

The C-reactive protein-albumin-lymphocyte (CALLY) index reflects systemic inflammation and immune and nutritional status. We investigated whether admission CALLY was associated with early hospital presentation or receipt of intravenous thrombolysis (IVT) in adults with acute ischemic stroke. This single-center retrospective study included 197 adults with acute ischemic stroke admitted between September 2018 and September 2024. All 98 patients who received IVT were included; 99 non-thrombolyzed controls were selected by computer-generated random sampling from a pool constructed using group-level frequency matching. CALLY was calculated as albumin (g/L) × lymphocyte count (×109/L)/[C-reactive protein (mg/L) × 10]. Early presentation was defined as onset-to-door time ≤4.5 hours. Multivariable logistic regression adjusted for age, sex, and National Institutes of Health Stroke Scale (NIHSS) score assessed associations of ln(CALLY) with early presentation and receipt of IVT. Patients who received IVT had higher NIHSS scores (median, 7 vs 1; P < .001) and lower CALLY values (median, 1.37 vs 2.64; P = .050); however, the CALLY difference was not significant after multiplicity correction (q = 0.122). CALLY was inversely correlated with NIHSS score (Spearman ρ = -0.29; P < .001). After adjustment, ln(CALLY) was not associated with receipt of IVT (adjusted odds ratio = 1.34; 95% confidence interval = 0.98-1.82; P = .063). Its borderline association with early presentation (adjusted odds ratio = 1.34; 95% confidence interval = 1.02-1.77; P = .036) was not consistent across sensitivity analyses. CALLY did not differ significantly between early and late presenters (P = .100). Lower CALLY values among patients receiving IVT were largely explained by greater stroke severity. No consistent independent association was found between CALLY and either outcome. These findings do not support using CALLY to guide thrombolytic decision-making.

PMID 43012800
Read full article →
PubMedImmunity, inflammation and disease2026-11-11

Rheumatoid Arthritis and Thrombocytopenia: Causal Evidence and Prognostic Implications From Observational and Mendelian Randomization Analyzes.

Wu Yejun Y, Cai Yuyang Y, Yang Anzhen A, Zhang Shuying S et al.

Rheumatoid arthritis (RA) is a systemic autoimmune disease associated with hematological abnormalities, and we aimed to investigate the clinical significance and causal relationship of thrombocytopenia (TP) in RA. We integrated observational data with genetic approaches, characterized the clinical features of RA patients with TP, and evaluated their prognostic implications. Data from the National Health and Nutrition Examination Survey were used to analyze clinical characteristics and survival outcomes of RA patients. Survey-weighted Cox regression models were applied to evaluate the association between TP and mortality. Two-sample Mendelian randomization (MR) analysis was performed to evaluate the causal relationship between RA and TP. Among 2667 RA participants with available platelet measurements, 135 had TP (< 150 × 109/L). In the common complete-case sample, TP remained associated with higher all-cause mortality after full survey-weighted adjustment (HR 1.92, 95% CI 1.17-3.16; p = 0.009). Lower serum albumin and higher urinary albumin concentration were also associated with mortality in the fully adjusted model. In the MR analysis using 52 SNPs, fixed-effect IVW yielded OR 1.054 (95% CI 1.002-1.108; p = 0.042), but alternative estimators were not significant and the MR-Egger intercept indicated directional pleiotropy (p = 0.0016). Thrombocytopenia was associated with poorer survival among RA participants, whereas MR did not provide robust evidence for a causal effect of RA liability on thrombocytopenia. These findings warrant further prospective validation.

PMID 43012374
Read full article →
PubMedMedicine2026-11-11

The prognostic value of the HALP score among patients diagnosed with Hodgkin lymphoma.

Ayer Mesut M, Tekin Gunhan G, Eker Edibe Sevde ES, Serin Istemi I

The hemoglobin, albumin, lymphocyte, and platelet (HALP) score is an immune-nutritional biomarker utilized for prognostic assessment in oncology patients. It is determined by the formula: hemoglobin (g/L) × albumin (g/L) × lymphocytes (×109/L)]/platelets (×109/L). The objective of this study is to evaluate the prognostic value of the HALP score and its association with treatment response and survival outcomes among patients diagnosed with Hodgkin lymphoma (HL). Patients diagnosed with HL at the Hematology Clinic of Istanbul Başakşehir Çam and Sakura City Hospital between January 1, 2020, and January 1, 2025, were included in this study. A total of 100 patients with HL were included in the study. Patients were categorized based on the median HALP score of 23.72. Patients with a low HALP score exhibited significantly higher rates of stage IV disease, presence of B symptoms, and bulky masses. Patients with a high HALP score demonstrated significantly more complete response and less progression at the end of treatment. The analysis revealed a statistically significant 2.82-fold (95% confidence intervals: 1.14-6.97) increased risk of progression in patients with a HALP score of <23.72 compared to those with a score of ≥23.72. Patients with lower HALP scores exhibited more adverse disease characteristics. Lower HALP scores were associated with adverse disease characteristics, poorer treatment response, and shorter progression-free survival; however, HALP did not remain an independent prognostic factor in multivariate analysis.

PMID 43012787
Read full article →
PubMedBMC nephrology2026-11-11

Age-related clinical risk patterns of acute kidney injury and tubular injury in adults with minimal change disease: a retrospective cohort study.

Fu Yilin Y, Tang Jia J, Zhou Ziqi Z, Wang Ruoxiao R et al.

Adult patients with minimal change disease (MCD), particularly older individuals, may experience acute kidney injury (AKI), tubular injury, and infectious complications. However, the clinical patterns associated with these complications remain incompletely understood. This study aimed to characterize age-related clinical features and the associations of selected clinical variables with renal and infectious complications in adults with biopsy-proven primary MCD. We retrospectively analyzed 225 adults with biopsy-proven primary MCD and classified them into patients aged 18-59 years and those aged ≥ 60 years. Clinical characteristics, renal outcomes, infection status, treatment exposure, and medication exposure were extracted from electronic medical records. Multivariable logistic regression models incorporating restricted cubic splines (RCS) were used to evaluate potential nonlinear associations. The UA-AKI model was adjusted for age, sex, hematuria, diabetes mellitus, systolic blood pressure, and 24-hour urinary protein. The age-tubular injury model was adjusted for serum uric acid, sex, hematuria, diabetes mellitus, systolic blood pressure, and 24-hour urinary protein. Serum albumin and documented CKD history were included in sensitivity analyses where appropriate. Compared with patients aged 18-59 years, those aged ≥ 60 years had higher rates of AKI (44.1% vs. 22.7%, P = 0.001), pathology-reported tubular injury (36.6% vs. 17.4%, P = 0.002), and clinically documented infection (40.9% vs. 21.2%, P = 0.002). RCS analyses showed that admission serum uric acid was significantly and nonlinearly associated with AKI (Poverall < 0.001; Pnonlinear = 0.004). This association remained robust after additional adjustment for serum albumin and documented CKD history (Poverall < 0.001; Pnonlinear = 0.006). Age was significantly associated with pathology-reported tubular injury (Poverall = 0.021), without evidence of significant nonlinearity (Pnonlinear = 0.253). The age-tubular injury association remained significant after additional adjustment for documented CKD history and after further adjustment for both serum albumin and documented CKD history. Older patients also had higher serum IgG levels than younger patients, including within infection-stratified subgroups. In adults with biopsy-proven primary MCD, admission serum uric acid was nonlinearly associated with AKI, whereas age was associated with pathology-reported tubular injury without evidence of significant nonlinearity. Older patients had higher rates of AKI, clinically documented infection, and pathology-reported tubular injury. These findings highlight age-related heterogeneity in renal and infectious complications among adults with MCD, although causal inference is limited by the retrospective design. Not applicable. This study was a retrospective observational study and was not a clinical trial.

PMID 43009838
Read full article →
PubMedMedicine2026-11-11

Association between nursing assessment indicators and adverse outcomes in hospitalized patients with atrial fibrillation: A retrospective observational study.

Han Jie J, Liu Siyu S, Li Nan N, Zhang Ruiqin R

This retrospective observational study examines the association between routinely collected admission nursing assessment indicators and in-hospital adverse outcomes among hospitalized patients with atrial fibrillation (AF). A total of 312 hospitalized patients with AF admitted to a tertiary teaching hospital between January 2021 and December 2024 were included. The Morse Fall Scale, Barthel Index, Nutritional Risk Screening 2002 (NRS-2002), and Braden Scale were assessed within 24 hours of admission. Clinical characteristics, vital signs, and laboratory data were extracted from electronic medical records. The composite adverse outcome comprised in-hospital death, unplanned intensive care unit admission, worsening heart failure requiring treatment escalation, major bleeding requiring medical intervention, or thromboembolic events. Univariable and multivariable logistic regression analyses were used to examine associations with the composite outcome. Among 312 patients, 68 (21.8%) experienced at least one adverse outcome. In the adjusted analysis, a higher Morse Fall Scale score was associated with higher odds of adverse outcomes (OR 1.031, 95% CI 1.012-1.051; P = .002), whereas a higher Barthel Index score was associated with lower odds (OR 0.978, 95% CI 0.961-0.995; P = .012). A higher NRS-2002 score was associated with higher odds (OR 1.376, 95% CI 1.083-1.748; P = .009), and a higher serum albumin level was associated with lower odds (OR 0.953, 95% CI 0.920-0.988; P = .010). AF type and Braden Scale score were not independently associated with the composite outcome after adjustment. Admission nursing assessments of fall risk, functional status, and nutritional risk, together with serum albumin, were independently associated with in-hospital adverse outcomes. These results support their use as complementary markers of vulnerability and for closer clinical surveillance, but they do not establish causality or justify changing guideline-directed AF treatment. Prospective multicenter studies are required before these measures can be incorporated into validated clinical decision tools.

PMID 43012841
Read full article →

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about albumin